CONNEQT Health has raised A$5.5 million through a two-tranche placement at a 15.4% discount, backed by key shareholders, to accelerate its commercial expansion and product development.
- A$5.5 million raised via two-tranche placement
- Placement priced at A$0.022 per share, 15.4% discount
- C2 Ventures commits A$1.5 million subject to approval
- Share Purchase Plan to raise up to A$0.5 million
- Annualised revenue run-rate approaches A$10 million
Capital Raise Targets Accelerated Growth
CONNEQT Health (ASX:CQT) has successfully secured A$5.5 million through a two-tranche placement priced at A$0.022 per share, reflecting a 15.4% discount to the last closing price of A$0.026. The raise, strongly supported by both existing and new sophisticated investors, aims to fuel the commercial expansion of its flagship CONNEQT Pulse arterial health monitor and support ongoing product development and enterprise growth initiatives.
The placement shares will be issued in two tranches, with the first tranche of approximately 160.9 million shares expected to settle on 25 June 2026. The second tranche, comprising about 89.1 million shares, awaits shareholder approval at an upcoming Extraordinary General Meeting.
Shareholder Participation and Support
In a show of confidence, C2 Ventures, associated with Chairman Niall Cairns and CEO Craig Cooper, has committed to invest A$1.5 million in the placement, subject to shareholder approval. Additionally, CONNEQT plans to offer eligible shareholders a Share Purchase Plan (SPP) on the same terms as the placement, targeting an additional raise of up to A$0.5 million. The company reserves discretion to accept oversubscriptions or scale back applications.
Strong Commercial Momentum Underpins Raise
The capital injection comes on the back of robust commercial progress. CONNEQT reported quarterly revenue of A$2.04 million in its March 2026 quarter, pushing its annualised group revenue run-rate to around A$10 million. The Pulse device remains the primary growth engine, contributing approximately A$7 million of that run-rate and sustaining an average quarterly growth rate exceeding 50% since launch.
Independent validation of the Pulse’s market position arrived with recognition from the American Association of Retired Persons, naming it one of the “Best Blood Pressure Monitors of 2026” and awarding the highest rating for “Most Comprehensive Data.” Meanwhile, the enterprise channel continues to gain traction, with pilot programs converting fully to commercial contracts and clinical subscription sites expanding.
Operational Efficiency and Outlook
CONNEQT has also trimmed its operating expenses by approximately 30% since Q3 FY25, excluding non-cash items and customer acquisition costs, enhancing scalability and edging closer to profitability. CEO Craig Cooper emphasised that the capital raise positions the company to accelerate inventory build, product and software development, marketing, and expansion of high-margin recurring revenue streams underpinning long-term value.
Cooper highlighted the company’s transformation from a traditional medical device maker to a scalable connected health platform within just 17 months, driven by strong Pulse sales growth and enterprise channel expansion. The raise is expected to support CONNEQT’s ambitions to build a category-leading cardiovascular health platform.
Bottom Line?
The raise bolsters CONNEQT’s runway to capitalise on rising demand for its Pulse device and enterprise offerings, but shareholder approval for the second tranche and SPP uptake remain key near-term uncertainties.
Questions in the middle?
- Will shareholder approval for the second tranche proceed smoothly at the upcoming meeting?
- How will the company manage potential oversubscriptions or scale-backs in the Share Purchase Plan?
- Can CONNEQT sustain its rapid Pulse revenue growth while expanding its enterprise subscription base?